source
- Amylyx's avexitide halves hypoglycemia episodes in phase 3 trial for post‑bariatric patientsAmylyx Pharmaceuticals reported that its GLP‑1 receptor antagonist avexitide significantly reduced dangerous blood‑sugar drops in a phase 3 study. The double‑blind Lucidity trial enrolled 78 indiv…
- Drugmakers Back US Probe into Germany’s New Drug Pricing PoliciesSeven major pharmaceutical companies, together with industry groups PhRMA and BIO, have urged the German government to amend its recently introduced drug‑pricing reforms. The coalition voiced supp…